World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia–a short version for primary care

WFSBP Task Force on Treatment Guidelines for Schizophrenia

Resultado de la investigación: Review article

10 Citas (Scopus)

Resumen

Objective: Schizophrenia is a severe mental disorder and many patients are treated in primary care settings. Apart from the pharmacological management of disease-associated symptoms, the detection and treatment of side effects is of the utmost importance in clinical practice. The purpose of this publication is to offer relevant evidence-based recommendations for the biological treatment of schizophrenia in primary care. Methods: This publication is a short and practice-oriented summary of Parts I–III of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. The recommendations were developed by the authors and consented by a task force of international experts. Guideline recommendations are based on randomized-controlled trials and supplemented with non-randomized trials and meta-analyses where necessary. Results: Antipsychotics of different chemical classes are the first-line pharmacological treatments for schizophrenia. Specific circumstances (e.g., suicidality, depression, substance dependence) may need additional treatment options. The pharmacological and non-pharmacological management of side effects is of crucial importance for the long-term treatment in all settings of the healthcare system. Conclusions: This summary of the three available evidence-based guidelines has the potential to support clinical decisions and can improve treatment of schizophrenia in primary care settings.

Idioma originalEnglish
Páginas (desde-hasta)82-90
Número de páginas9
PublicaciónInternational Journal of Psychiatry in Clinical Practice
Volumen21
N.º2
DOI
EstadoPublished - 3 abr 2017

Huella dactilar

Biological Psychiatry
Primary Health Care
Guidelines
Schizophrenia
Pharmacology
Therapeutics
Clinical Decision Support Systems
Advisory Committees
Disease Management
Mental Disorders
Antipsychotic Agents
Substance-Related Disorders
Meta-Analysis
Randomized Controlled Trials
Depression
Delivery of Health Care

ASJC Scopus subject areas

  • Psychiatry and Mental health

Citar esto

@article{41fd6d7716904b77ad152f3ea983fd2c,
title = "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia–a short version for primary care",
abstract = "Objective: Schizophrenia is a severe mental disorder and many patients are treated in primary care settings. Apart from the pharmacological management of disease-associated symptoms, the detection and treatment of side effects is of the utmost importance in clinical practice. The purpose of this publication is to offer relevant evidence-based recommendations for the biological treatment of schizophrenia in primary care. Methods: This publication is a short and practice-oriented summary of Parts I–III of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. The recommendations were developed by the authors and consented by a task force of international experts. Guideline recommendations are based on randomized-controlled trials and supplemented with non-randomized trials and meta-analyses where necessary. Results: Antipsychotics of different chemical classes are the first-line pharmacological treatments for schizophrenia. Specific circumstances (e.g., suicidality, depression, substance dependence) may need additional treatment options. The pharmacological and non-pharmacological management of side effects is of crucial importance for the long-term treatment in all settings of the healthcare system. Conclusions: This summary of the three available evidence-based guidelines has the potential to support clinical decisions and can improve treatment of schizophrenia in primary care settings.",
keywords = "primary care, schizophrenia, WFSBP treatment guidelines",
author = "{WFSBP Task Force on Treatment Guidelines for Schizophrenia} and Alkomiet Hasan and Peter Falkai and Thomas Wobrock and Jeffrey Lieberman and Birte Glenth{\o}j and Gattaz, {Wagner F.} and Florence Thibaut and M{\"o}ller, {Hans J{\"u}rgen} and {Carlo Altamura}, A. and Nancy Andreasen and Barnes, {Thomas R.E.} and {Emin Ceylan}, M. and Ollivier, {Jorge Ciprian} and Timothy Crow and Danaci, {Aysen Esen} and Anthony David and Michael Davidson and Bill Deakin and Helio Elkis and Lars Farde and Wolfgang Gaebel and Bernd Gallhofer and Jes Gerlach and Hirsch, {Steven Richard} and Hojaij, {Carlos Roberto} and Michael Hwang and Hwo, {Hai Gwo} and Jablensky, {Assen Verniaminov} and Marek Jarema and John Kane and Takuja Kojima and Veronica Larach and Jeffrey Lieberman and Patrick McGorry and Herbert Meltzer and M{\"o}ller, {Hans J{\"u}rgen} and Sergey Mosolov and Driss Moussaoui and Oli{\'e}, {Jean Pierre} and Palha, {Antonio Pacheco} and Asli Sarand{\"o}l and Mitsumoto Sato and Heinrich Sauer and Nina Schooler and Bilgen Taneli and {von Knorring}, Lars and Daniel Weinberger and Shigeto Yamawaki",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/13651501.2017.1291839",
language = "English",
volume = "21",
pages = "82--90",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "2",

}

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia–a short version for primary care. / WFSBP Task Force on Treatment Guidelines for Schizophrenia.

En: International Journal of Psychiatry in Clinical Practice, Vol. 21, N.º 2, 03.04.2017, p. 82-90.

Resultado de la investigación: Review article

TY - JOUR

T1 - World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia–a short version for primary care

AU - WFSBP Task Force on Treatment Guidelines for Schizophrenia

AU - Hasan, Alkomiet

AU - Falkai, Peter

AU - Wobrock, Thomas

AU - Lieberman, Jeffrey

AU - Glenthøj, Birte

AU - Gattaz, Wagner F.

AU - Thibaut, Florence

AU - Möller, Hans Jürgen

AU - Carlo Altamura, A.

AU - Andreasen, Nancy

AU - Barnes, Thomas R.E.

AU - Emin Ceylan, M.

AU - Ollivier, Jorge Ciprian

AU - Crow, Timothy

AU - Danaci, Aysen Esen

AU - David, Anthony

AU - Davidson, Michael

AU - Deakin, Bill

AU - Elkis, Helio

AU - Farde, Lars

AU - Gaebel, Wolfgang

AU - Gallhofer, Bernd

AU - Gerlach, Jes

AU - Hirsch, Steven Richard

AU - Hojaij, Carlos Roberto

AU - Hwang, Michael

AU - Hwo, Hai Gwo

AU - Jablensky, Assen Verniaminov

AU - Jarema, Marek

AU - Kane, John

AU - Kojima, Takuja

AU - Larach, Veronica

AU - Lieberman, Jeffrey

AU - McGorry, Patrick

AU - Meltzer, Herbert

AU - Möller, Hans Jürgen

AU - Mosolov, Sergey

AU - Moussaoui, Driss

AU - Olié, Jean Pierre

AU - Palha, Antonio Pacheco

AU - Sarandöl, Asli

AU - Sato, Mitsumoto

AU - Sauer, Heinrich

AU - Schooler, Nina

AU - Taneli, Bilgen

AU - von Knorring, Lars

AU - Weinberger, Daniel

AU - Yamawaki, Shigeto

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Objective: Schizophrenia is a severe mental disorder and many patients are treated in primary care settings. Apart from the pharmacological management of disease-associated symptoms, the detection and treatment of side effects is of the utmost importance in clinical practice. The purpose of this publication is to offer relevant evidence-based recommendations for the biological treatment of schizophrenia in primary care. Methods: This publication is a short and practice-oriented summary of Parts I–III of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. The recommendations were developed by the authors and consented by a task force of international experts. Guideline recommendations are based on randomized-controlled trials and supplemented with non-randomized trials and meta-analyses where necessary. Results: Antipsychotics of different chemical classes are the first-line pharmacological treatments for schizophrenia. Specific circumstances (e.g., suicidality, depression, substance dependence) may need additional treatment options. The pharmacological and non-pharmacological management of side effects is of crucial importance for the long-term treatment in all settings of the healthcare system. Conclusions: This summary of the three available evidence-based guidelines has the potential to support clinical decisions and can improve treatment of schizophrenia in primary care settings.

AB - Objective: Schizophrenia is a severe mental disorder and many patients are treated in primary care settings. Apart from the pharmacological management of disease-associated symptoms, the detection and treatment of side effects is of the utmost importance in clinical practice. The purpose of this publication is to offer relevant evidence-based recommendations for the biological treatment of schizophrenia in primary care. Methods: This publication is a short and practice-oriented summary of Parts I–III of the World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. The recommendations were developed by the authors and consented by a task force of international experts. Guideline recommendations are based on randomized-controlled trials and supplemented with non-randomized trials and meta-analyses where necessary. Results: Antipsychotics of different chemical classes are the first-line pharmacological treatments for schizophrenia. Specific circumstances (e.g., suicidality, depression, substance dependence) may need additional treatment options. The pharmacological and non-pharmacological management of side effects is of crucial importance for the long-term treatment in all settings of the healthcare system. Conclusions: This summary of the three available evidence-based guidelines has the potential to support clinical decisions and can improve treatment of schizophrenia in primary care settings.

KW - primary care

KW - schizophrenia

KW - WFSBP treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=85013815374&partnerID=8YFLogxK

U2 - 10.1080/13651501.2017.1291839

DO - 10.1080/13651501.2017.1291839

M3 - Review article

VL - 21

SP - 82

EP - 90

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 2

ER -